Key Takeaways
- Strong headline growth, softer underlying quarter: Net income grew 19% YoY to ₹533.98 crores, but sequential margins dipped on product mix, logistics delays, and rising input costs.
- ATBS demand outstrips supply: Demand for very high-grade ATBS now restricts effective production capacity, making the H2 FY25 expansion the critical catalyst.
- New products are a FY26 story, not FY25: The MEHQ-Guaiacol plant is on stream but not stabilized; meaningful revenue from the VOPL subsidiary’s capex is pushed to FY26.
- Management held the 20% CAGR line: The guidance factors in output from the ₹800 crores capex program, with both ATBS and VOPL projects completing in H2 FY25.
- What to watch next quarter: Whether logistics bottlenecks clear and raw material pass-throughs restore Q1’s lost margin, and any stabilization update on the MEHQ plant.
ATBS: The Capacity Constraint
- Demand ceiling is self-imposed: Demand exceeds supply specifically because customers require very high-grade ATBS, which restricts the throughput of existing lines.
- Mix shift is structural: Over 70% of ATBS volumes are now high-grade, driven by customer pull rather than a Vinati-led push.
- Margin neutrality on grade: The shift to high-grade ATBS carries no meaningful margin uplift because the higher selling price is offset by higher production cost.
- Domestic pull emerging: Indian customers are beginning to make ATBS polymer locally now that the monomer is available domestically, adding a new demand layer.
- Expansion is the unlock: Expanded ATBS capacity is expected to come into play from FY26, with project completion slated for H2 FY25.
Vinati Saraf Mutreja: "See, in ATBS right now, the demand exceeds the supply. Because the demand, which is there, it's for a very, very high grade ATBS quality, which restricts our production capacity. So really, the efforts are now towards commercializing our new line as soon as possible."
VOPL & New Products: The FY26 Bridge
- Subsidiary formed, capex outlined: Veeral Organics Private Limited (VOPL), a 100% subsidiary, will execute a capex plan exceeding ₹500 crores for MEHQ, Guaiacol, Anisole, 4-meth, and other Iso Amylene derivatives.
- MEHQ-Guaiacol is live but immature: The plant is on stream with commercial samples sent and some sales booked, but it is not fully stabilized; management is still working on efficiency and yield.
- Revenue pushed out: Meaningful revenue contributions from MEHQ are expected only from FY26 onwards; FY25 sales will be very meagre.
- Market access in progress: MEHQ demand is mainly in China; Guaiacol has demand in India; sampling is underway through traders for export, with some self-consumption of MEHQ.
- Anisole dual-purpose: Some external sales are assumed, but part of the capacity is intended for captive consumption.
- Remaining VOPL products: Commissioning for the other products under the VOPL capex is scheduled for H2 FY25.
Margins: A Q1 Trough with a Q3/Q4 Promise
- Sequential compression explained: Q1 margins are always lower than Q4 because Q4 is seasonally the highest; this quarter added product mix changes, raw material cost increases, and logistics delays.
- Input cost headwinds: Raw material prices increased during Q1, with pass-through to customers expected in Q2; electricity prices rose ~10% on a unit basis, and coal prices also increased.
- Logistics friction: Significant tanker unavailability and delays left inventory in transit at quarter-end, pushing some sales recognition into Q2.
- High-margin products back-loaded: Customized products, which carry higher margins, typically arrive in Q3 and Q4.
- Recovery path: Management acknowledged margins were "a little bit suppressed" in Q1 and expects a pickup in Q3 and Q4.
Vinati Saraf Mutreja: "if you are willing to pay more, you are able to get the container. Okay. But if there is some delay, you have to wait. The supply chain has to be managed. That's all."
Antioxidants: Gradual Recovery Underway
- Growth despite weak global demand: Vinati is seeing good growth in antioxidant sales in FY25 even as global demand remains soft.
- Utilization target: Management expects to reach approximately 50% capacity utilization in FY25.
- India-led recovery: The AO business, used in plastics and polymers, has shown good growth in India over the last three years after a slow two-year period; management expects the pickup to continue.
- Portfolio expansion on the horizon: R&D work on adding new niche antioxidants to the basket is ongoing, though no timeline has been given for a go-ahead decision.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| ATBS expansion completion | Project completion | H2 FY25 |
| ATBS capacity contribution | Expanded capacity aids growth | FY26 onwards |
| VOPL remaining products commissioning | Products under ₹500+ crores capex | H2 FY25 |
| MEHQ meaningful revenue | Material revenue contribution begins | FY26 onwards |
| Antioxidant capacity utilization | Reach ~50% utilization | FY25 |
| Revenue CAGR | 20% CAGR over three years, factoring in ₹800 crores capex output | Over three years |
| Raw material pass-through | Price increases passed through to customers | Q2 |
Key Metrics
| Metric | Q1 FY25 |
|---|---|
| Net income | ₹533.98 cr, +19% YoY vs ₹448.5 cr (restated) |
| EBIT | ₹114.8 cr, +23% YoY vs ₹93.44 cr |
| PAT | ₹86 cr, +24% YoY vs ₹69.42 cr |
| Revenue growth guidance | 20% CAGR over three years, on track |
| ATBS revenue share | ~33% of total revenue |
| IBB revenue share | ~15% of total revenue |
| Butylphenol and IB derivatives revenue share | ~21% of total revenue |
| Antioxidants revenue share | ~8% of total revenue |
| IB and HPMTBE revenue share | ~12% of total revenue |
| Customized products revenue share | ~4% of total revenue |
| High-grade ATBS proportion | >70% of total ATBS volumes |
| ATBS export proportion | 90–95% of ATBS sales |
| Capex for FY25 | ₹500–570 cr, including ATBS expansion and VOPL |
| VOPL capex plan | >₹500 cr total outlay |
| ATBS expansion capex | ₹300 cr total outlay |
| Renewable energy share | 40–50% of total energy consumption |
| Electricity cost increase | ~10% rise on a unit basis |
| Dividend payout ratio | 20% |